Wedbush Maintains Outperform on Climb Bio, Raises Price Target to $17
Benzinga Newsdesk 6 months ago
NewsPrice TargetAnalyst Ratings
Wedbush analyst Laura Chico maintains Climb Bio (NASDAQ:CLYM) with a Outperform and raises the price target from $15 to $17.
Wedbush analyst Laura Chico maintains Climb Bio (NASDAQ:CLYM) with a Outperform and raises the price target from $15 to $17.